More OMQ Letters After FDA Inspections? Don't Treat Them as Noise
We're hearing that manufacturers are getting more post-inspection mail from CDER. Here's what the letters actually mean for your next inspection.
We’ve recently heard from a few drug manufacturers that they’re seeing more post-inspection correspondence from CDER's Office of Manufacturing Quality, even after inspections that ended with one or two Form FDA 483 observations.
One VP of Quality at a major pharma company described it plainly: he's been seeing more OMQ letters, even post-EIR, with only a single observation. His theory was that the FDA might be padding activity to justify headcount and budget.
That could certainly be part of it. The (maybe) more likely explanation is that this is the FDA’s existing inspection closeout process running as designed, now executed more consistently and visibly than many firms are used to.
What these letters actually are
The letters these manufacturers are receiving are likely inspection classification decisional letters associated with the FDA’s FMD-145/EIR release process. They’re how the FDA communicates an inspection’s final classification to the facility.
The FDA began issuing 90-day facility classification decisional letters in late 2017 as part of a Concept of Operations (ConOps) agreement between CDER and ORA.
The program was a direct commitment under GDUFA II. The agency agreed to communicate final surveillance inspection classifications to facility owners within 90 days of an inspection. According to the FDA’s ConOps Q&A page, there are separate letter templates depending on whether the inspection is classified as NAI, VAI, or OAI.
How the post-inspection process works
The workflow is spelled out in the FDA’s Drug Manufacturing Inspections Compliance Program (7356.002) and the ConOps agreement.
For surveillance inspections, ORA completes the Establishment Inspection Report and an initial classification within 45 days of closing the inspection. If the initial classification is potentially OAI, ORA refers the package to OMQ within those same 45 days. OMQ then makes a final classification and issues a decisional letter within 90 days of the inspection's close.
For VAI or OAI initial classifications, the inspectional package goes to a CDER Compliance Officer for review. For API, OTC, and many small molecule drug products, that review sits in OMQ. For biologics and certain product-specific programs, review responsibilities may sit in other CDER offices, such as the Office of Pharmaceutical Manufacturing Assessment (OPMA). The Compliance Officer has 45 days from receipt of the complete package to determine the final classification.
If no further action is recommended, whether because of an NAI classification, a VAI classification, or a downgraded OAI, ORA issues the FMD-145 decisional letter within the 90-day window.
You can see the actual NAI letter template and the OAI letter template on the FDA’s website.
The NAI letter is pretty simple. It states the inspection classification, notes that the facility is in an acceptable state of CGMP compliance, and includes a copy of the redacted EIR. It also includes a line that this letter does not constitute an endorsement.
Why firms may be seeing more of them now
We’re speculating a bit here, but a few factors are probably working together:
The FDA is simply doing more inspections, and this is a natural result. In FY2024, the agency conducted 989 drug quality assurance inspections, a 27% increase from FY2023. More than 62% of those were at foreign sites, an all-time high. More inspections mean more classification letters.
The ConOps program has also matured. When the FDA first began issuing 90-day decisional letters in late 2017, the goal was 90% compliance with the 90-day timeline. Seven years in, the process is likely more well-established, and the letter issuance rate is more consistent. Firms that went years between inspections during COVID may be encountering this for the first time now that the FDA has resumed normal surveillance schedules.
And the enforcement trend is real. The FDA issued 105 warning letters for drug quality issues in FY2024, the highest number in five years. Inspection-driven warning letters increased 21% from FY2023. The agency is issuing more inspection-driven correspondence alongside increased inspection activity, and classification letters are part of that broader process.
What the letters mean for your facility
A classification letter after an inspection is not by itself enforcement. For NAI and VAI outcomes, it’s the formal record that the FDA has reviewed your inspection and decided not to pursue regulatory or enforcement action.
But VAI means something. The FDA’s Inspection Classification Database defines VAI as a classification indicating that the inspection found objectionable conditions, but the agency expects the facility to correct them voluntarily. The database also states that if a manufacturer fails to implement voluntary corrections, the next inspection may be classified as OAI.
That escalation path is explicit and documented. It’s the compliance signal that matters here.
